EX-99.1 2 exh991-pressreleaseq316.htm EXHIBIT 99.1 Exhibit


logoa02a01a01a09.jpg
Castlight Health Announces Third Quarter 2016 Results

Total Revenue of $25.5 Million, Up 31% Y-o-Y
GAAP & Non-GAAP Gross Margin Increases by 1,300+ Basis Points Y-o-Y
GAAP & Non-GAAP Operating Loss Reduced by $9 Million and $10 Million Y-o-Y, Respectively

SAN FRANCISCO - November 2, 2016 - Castlight Health, Inc. (NYSE:CSLT), a leading health benefits platform provider, today announced results for its third quarter ended September 30, 2016.

“We were pleased to pass a milestone during the third quarter by reaching $100 million in annualized revenue run rate. We also added 14 net new logos, with a majority of our new customers buying our full platform solution,” said Giovanni Colella, M.D., co-founder and chief executive officer of Castlight Health. “As the market increasingly moves toward mainstream buyers, we see growing demand for a comprehensive, cloud-based platform that addresses a broad range of health benefits challenges. We believe Castlight is a natural platform to drive utilization across multiple solutions, positioning us well in a multi-billion dollar market opportunity.” 

Financial Performance for the Three Months Ended September 30, 2016

•
Total revenue for the third quarter of 2016 was $25.5 million, an increase of 31% from the third quarter of 2015. Subscription revenue was $23.9 million, an increase of 31% on a year-over-year basis.





•
Gross margin for the third quarter of 2016 was 68.8%, compared to a gross margin of 55.5% in the third quarter of 2015. Non-GAAP gross margin for the third quarter of 2016 was 72.1% compared to a non-GAAP gross margin of 59.3% in the third quarter of 2015.

•
Operating loss for the third quarter of 2016 was $11.5 million, compared to an operating loss of $20.1 million in the third quarter of 2015. Non-GAAP operating loss for the third quarter of 2016 was $5.5 million, compared to a non-GAAP operating loss of $15.9 million in the third quarter of 2015.

•
Net loss per basic and diluted share was $0.11 in the third quarter of 2016, compared to a net loss per basic and diluted share of $0.21 in the third quarter of 2015. The non-GAAP net loss per basic and diluted share for the third quarter of 2016 was $0.05, compared to a net loss per basic and diluted share of $0.17 in the third quarter of 2015. For both GAAP and non-GAAP purposes, the weighted average basic and diluted share count for the third quarter of 2016 was 103.1 million compared to 94.4 million in the third quarter of 2015.

•
Total cash, cash equivalents and marketable securities were $116.4 million at the end of the third quarter of 2016. Cash used in operations for the third quarter of 2016 was $9.4 million, compared to $14.5 million used in operations in the third quarter of 2015.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”.

“Over the last 5 quarters, we have reduced our quarterly non-GAAP operating expenses by 16% while non-GAAP gross margins have increased by 1,300 basis points and our revenue run




rate has grown by 38%. Along the way, we have continued to increase investments in product development while also putting in place strategic channel partners that we expect will drive growth in our business during 2017 and beyond,” said John Doyle, President and COO of Castlight Health. “The reduction of our third quarter non-GAAP operating loss to the lowest level in 4 years puts us well on track to bringing our business to cash flow break-even in mid-2017, and positioning us with a meaningful cash balance to continue funding our strategic growth initiatives.” 

Business Outlook
Full Year 2016 Guidance: The Company continues to expect revenue to track toward the mid-point of its $99.0 million to $102.0 million guidance range for the full year 2016. The Company expects to outperform its previously issued non-GAAP operating loss guidance range of $40.0 million to $42.0 million, as well as its previously issued non-GAAP net loss per share guidance range of $0.40 to $0.42 based on 100 million to 101 million weighted average basic and diluted common shares outstanding.

For the full year 2016, non-GAAP guidance excludes the effects of stock-based compensation expense, charge related to reduction in workforce and the capitalization and amortization of internal-use software.

Quarterly Conference Call

Castlight Health will host a conference call to discuss its third quarter 2016 results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the company’s Investor Relations website at http://ir.castlighthealth.com. In addition, an archive of the webcast can be accessed




through the same link. Participants who choose to call in to the conference call can do so by dialing 1-866-393-4306. The conference ID number is 94707357. A replay will be available for one week at 1-855-859-2056, passcode 94707357.

About Castlight Health

Our mission is to empower people to make the best choices for their health and to help companies make the most of their health benefits. We offer a health benefits platform that engages employees to make better healthcare decisions and can guide them to the right program, care, and provider. The platform also enables benefit leaders to communicate and measure their programs while driving employee engagement with targeted, relevant communications. Castlight has partnered with enterprise customers, spanning millions of lives, to improve healthcare outcomes, lower costs, and increase benefits satisfaction.

For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and Like us on Facebook.

Non-GAAP Financial Measures

To supplement Castlight Health’s financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross margin, non-GAAP operating expense, non-GAAP operating loss, non-GAAP net loss and non-GAAP net loss per share. These non-GAAP financial measures differ from GAAP financial measures in that they exclude stock-based compensation, warrant expense, litigation




settlement, charges related to a reduction in workforce, and capitalization and amortization of internal-use software and the associated tax impact of these items, where applicable.

We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company’s core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company’s historical financial performance.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the full year 2016 to comparable GAAP operating loss and net loss per share guidance because we do not provide guidance for stock-based compensation expense and capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP operating loss. The factors that may impact our future stock-based compensation expense and capitalization and amortization of internal-use software are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort.

These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP. Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company’s financial information in its entirety and not rely on a single financial measure.

Safe Harbor For Forward-Looking Statements





This press release contains forward-looking statements about Castlight Health’s expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health’s 2016 full year projections, our expectations for future performance of our business, market growth and business conditions, future innovation by the company and future developments with respect to the digital healthcare industry. Statements including words such as “anticipate,” “believe,” “estimate,” “will,” “continue,” “expect,” or “future,” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health’s documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.

Copyright 2016 Castlight Health, Inc. Castlight Health® is the registered trademark of Castlight Health, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.







CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)

 
 
As of
 
September 30, 2016
 
December 31, 2015
 
 (unaudited)
 
 
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
55,108

 
$
19,150

Marketable securities
61,326

 
101,274

Accounts receivable, net
15,888

 
12,751

Deferred commissions
7,746

 
5,438

Prepaid expenses and other current assets
3,884

 
3,772

Total current assets
143,952

 
142,385

Property and equipment, net
5,912

 
6,896

Marketable securities, noncurrent
—

 
13,335

Restricted cash, noncurrent
1,000

 
1,000

Deferred commissions, noncurrent
3,861

 
4,923

Other assets
4,691

 
4,735

Total assets
$
159,416

 
$
173,274

Liabilities and stockholders’ equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
3,603

 
$
3,384

Accrued expenses and other current liabilities
4,894

 
4,550

Accrued compensation
7,146

 
11,477

Deferred revenue
30,730

 
26,590

Total current liabilities
46,373

 
46,001

Deferred revenue, noncurrent
6,700

 
7,522

Other liabilities, noncurrent
1,255

 
1,397

Total liabilities
54,328

 
54,920

Stockholders’ equity
105,088

 
118,354

Total liabilities and stockholders’ equity
$
159,416

 
$
173,274






CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Revenue:
 
 
 
 
 
 
 
Subscription
$
23,867

 
$
18,233

 
$
66,859

 
$
50,417

Professional services
1,634

 
1,306

 
4,944

 
3,583

Total revenue
25,501

 
19,539

 
71,803

 
54,000

Cost of revenue:
 
 
 
 
 
 
 
Cost of subscription (1)
3,988

 
3,081

 
12,218

 
8,532

Cost of professional services (1)
3,978

 
5,606

 
13,941

 
15,581

Total cost of revenue
7,966

 
8,687

 
26,159

 
24,113

Gross profit
17,535

 
10,852

 
45,644

 
29,887

Operating expenses:
 
 
 
 
 
 
 
Sales and marketing (1)
13,143

 
16,731

 
44,877

 
50,835

Research and development (1)
10,573

 
7,868

 
30,619

 
21,853

General and administrative (1)
5,338

 
6,311

 
19,902

 
18,291

Total operating expenses
29,054

 
30,910

 
95,398

 
90,979

Operating loss
(11,519
)
 
(20,058
)
 
(49,754
)
 
(61,092
)
Other income, net
116

 
51

 
304

 
230

Net loss
$
(11,403
)
 
$
(20,007
)
 
$
(49,450
)
 
$
(60,862
)
Net loss per share, basic and diluted
$
(0.11
)
 
$
(0.21
)
 
$
(0.50
)
 
$
(0.65
)
Weighted-average shares used to compute basic and diluted net loss per share
103,147

 
94,409

 
99,734

 
93,343

_______________________
(1)
Includes stock-based compensation expense as follows:

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Cost of revenue:
 
 
 
 
 
 
 
Cost of subscription
$
139

 
$
96

 
$
367

 
$
196

Cost of professional services
456

 
647

 
1,468

 
1,522

Sales and marketing
2,190

 
2,058

 
6,644

 
5,883

Research and development
1,631

 
981

 
4,300

 
2,344

General and administrative
1,236

 
1,177

 
3,476

 
3,100





CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Operating activities:
 
 
 
 
 
 
 
Net loss
$
(11,403
)
 
$
(20,007
)
 
$
(49,450
)
 
$
(60,862
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
 
 
 
 
Depreciation and amortization
822

 
468

 
2,407

 
1,378

Stock-based compensation
5,652

 
4,959

 
16,255

 
13,045

Amortization of deferred commissions
1,042

 
917

 
3,157

 
2,576

Accretion and amortization of marketable securities
101

 
299

 
406

 
1,126

Changes in operating assets and liabilities:
 
 
 
 
 
 
 
Accounts receivable
(3,397
)
 
(2,597
)
 
(3,137
)
 
(2,548
)
Deferred commissions
(1,479
)
 
(1,595
)
 
(4,403
)
 
(3,346
)
Prepaid expenses and other assets
745

 
792

 
(68
)
 
(1,026
)
Accounts payable
410

 
(542
)
 
300

 
716

Accrued expenses and other liabilities
(3,583
)
 
1,429

 
(4,046
)
 
(1,740
)
Deferred revenue
1,733

 
1,367

 
3,318

 
5,770

Net cash used in operating activities
(9,357
)
 
(14,510
)
 
(35,261
)
 
(44,911
)
Investing activities:
 
 
 
 
 
 
 
Restricted cash
—

 
—

 
—

 
(1,000
)
Investment in related party
—

 
(1,000
)
 
—

 
(4,125
)
Purchase of property and equipment
(345
)
 
(1,806
)
 
(1,587
)
 
(3,499
)
Purchase of marketable securities
(11,971
)
 
(67,366
)
 
(73,163
)
 
(86,324
)
Sales of marketable securities
—

 
—

 
—

 
5,000

Maturities of marketable securities
35,570

 
78,466

 
126,157

 
140,019

Net cash provided by investing activities
23,254

 
8,294

 
51,407

 
50,071

Financing activities:
 
 
 
 
 
 
 
Proceeds from the exercise of stock options
636

 
354

 
2,576

 
3,180

Proceeds from issuance of common stock and warrants
—

 
—

 
17,358

 
—

Payments of issuance costs
(76
)
 
—

 
(122
)
 
(94
)
Net cash provided by financing activities
560

 
354

 
19,812

 
3,086

 
 
 
 
 
 
 
 
Net increase (decrease) in cash and cash equivalents
14,457

 
(5,862
)
 
35,958

 
8,246

Cash and cash equivalents at beginning of period
40,651

 
31,533

 
19,150

 
17,425

Cash and cash equivalents at end of period
$
55,108

 
$
25,671

 
$
55,108

 
$
25,671






CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)


 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
June 30,
 
September 30,
 
September 30,
 
September 30,
 
2016
 
2016
 
2015
 
2016
 
2015
Gross profit:
 
 
 
 
 
 
 
 
 
GAAP gross profit subscription
$
19,879

 
$
17,861

 
$
15,152

 
$
54,641

 
$
41,885

Stock-based compensation
139

 
120

 
96

 
367

 
196

Amortization of internal-use software
244

 
244

 
24

 
732

 
72

Reduction in workforce
—

 
5

 
—

 
5

 
—

Non-GAAP gross profit subscription
$
20,262

 
$
18,230

 
$
15,272

 
$
55,745

 
$
42,153

GAAP gross margin subscription
83.3
 %
 
81.4
 %
 
83.1
 %
 
81.7
 %
 
83.1
 %
Non-GAAP gross margin subscription
84.9
 %
 
83.0
 %
 
83.8
 %
 
83.4
 %
 
83.6
 %
 
 
 
 
 
 
 
 
 
 
GAAP gross loss professional services
$
(2,344
)
 
$
(3,220
)
 
$
(4,300
)
 
$
(8,997
)
 
$
(11,998
)
Stock-based compensation
456

 
535

 
647

 
1,468

 
1,522

Capitalization of internal-use software
—

 
—

 
(33
)
 
—

 
(33
)
Reduction in workforce
4

 
99

 
—

 
103

 
—

Non-GAAP gross loss professional services
$
(1,884
)
 
$
(2,586
)
 
$
(3,686
)
 
$
(7,426
)
 
$
(10,509
)
GAAP gross margin professional services
(143
)%
 
(198
)%
 
(329
)%
 
(182
)%
 
(335
)%
Non-GAAP gross margin professional services
(115
)%
 
(159
)%
 
(282
)%
 
(150
)%
 
(293
)%
 
 
 
 
 
 
 
 
 
 
GAAP gross profit
$
17,535

 
$
14,641

 
$
10,852

 
$
45,644

 
$
29,887

Impact of non-GAAP adjustments
843

 
1,003

 
734

 
2,675

 
1,757

Non-GAAP gross profit
$
18,378

 
$
15,644

 
$
11,586

 
$
48,319

 
$
31,644

GAAP gross margin
68.8
 %
 
62.1
 %
 
55.5
 %
 
63.6
 %
 
55.3
 %
Non-GAAP gross margin
72.1
 %
 
66.3
 %
 
59.3
 %
 
67.3
 %
 
58.6
 %
 
 
 
 
 
 
 
 
 
 
Operating expense:
 
 
 
 
 
 
 
 
 
GAAP sales and marketing
$
13,143

 
$
15,452

 
$
16,731

 
$
44,877

 
$
50,835

Stock-based compensation
(2,190
)
 
(2,219
)
 
(2,058
)
 
(6,644
)
 
(5,883
)
Reduction in workforce
(48
)
 
(374
)
 
—

 
(422
)
 
—

Non-GAAP sales and marketing
$
10,905

 
$
12,859

 
$
14,673

 
$
37,811

 
$
44,952

GAAP research and development
$
10,573

 
$
9,961

 
$
7,868

 
$
30,619

 
$
21,853

Stock-based compensation
(1,631
)
 
(1,264
)
 
(981
)
 
(4,300
)
 
(2,344
)
Capitalization of internal-use software
—

 
—

 
841

 
—

 
1,636

Reduction in workforce
(18
)
 
(118
)
 
—

 
(136
)
 
—

Non-GAAP research and development
$
8,924

 
$
8,579

 
$
7,728

 
$
26,183

 
$
21,145

GAAP general and administrative
$
5,338

 
$
6,019

 
$
6,311

 
$
19,902

 
$
18,291

Stock-based compensation
(1,236
)
 
(971
)
 
(1,177
)
 
(3,476
)
 
(3,100
)
Litigation settlement
—

 
(141
)
 
—

 
(2,876
)
 
—

Reduction in workforce
(10
)
 
(80
)
 
—

 
(90
)
 
—

Non-GAAP general and administrative
$
4,092

 
$
4,827

 
$
5,134

 
$
13,460

 
$
15,191

GAAP operating expense
$
29,054

 
$
31,432

 
$
30,910

 
$
95,398

 
$
90,979

Impact of non-GAAP adjustments
(5,133
)
 
(5,167
)
 
(3,375
)
 
(17,944
)
 
(9,691
)
Non-GAAP operating expense
$
23,921

 
$
26,265

 
$
27,535

 
$
77,454

 
$
81,288

 
 
 
 
 
 
 
 
 
 
Operating loss:
 
 
 
 
 
 
 
 
 
GAAP operating loss
$
(11,519
)
 
$
(16,791
)
 
$
(20,058
)
 
$
(49,754
)
 
$
(61,092
)
Impact of non-GAAP adjustments
5,976

 
6,170

 
4,109

 
20,619

 
11,448

Non-GAAP operating loss
$
(5,543
)
 
$
(10,621
)
 
$
(15,949
)
 
$
(29,135
)
 
$
(49,644
)
 
 
 
 
 
 
 
 
 
 
Net loss and net loss per share:
 
 
 
 
 
 
 
 
 
GAAP net loss
$
(11,403
)
 
$
(16,692
)
 
$
(20,007
)
 
$
(49,450
)
 
$
(60,862
)
Total pre-tax impact of non-GAAP adjustments
5,976

 
6,170

 
4,109

 
20,619

 
11,448

Income tax impact of non-GAAP adjustments
—

 
—

 
—

 
—

 
—

Non-GAAP net loss
$
(5,427
)
 
$
(10,522
)
 
$
(15,898
)
 
$
(28,831
)
 
$
(49,414
)
GAAP net loss per share, basic and diluted
$
(0.11
)
 
$
(0.17
)
 
$
(0.21
)
 
$
(0.50
)
 
$
(0.65
)
Non-GAAP net loss per share, basic and diluted
$
(0.05
)
 
$
(0.11
)
 
$
(0.17
)
 
$
(0.29
)
 
$
(0.53
)
Shares used in basic and diluted net loss per share computation
103,147

 
99,728

 
94,409

 
99,734

 
93,343





Investor Contact:
Seth Teich
ir@castlighthealth.com
415-829-1400
Media Contact:
Jim Rivas
press@castlighthealth.com
415-829-1568